Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy
Authors
Keywords
Bladder cancer, Immunotherapy, CXCL13, Tertiary lymphoid structures, Response to immunotherapy
Journal
EUROPEAN JOURNAL OF CANCER
Volume 148, Issue -, Pages 181-189
Publisher
Elsevier BV
Online
2021-03-19
DOI
10.1016/j.ejca.2021.01.036
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- B cells are associated with survival and immunotherapy response in sarcoma
- (2020) Florent Petitprez et al. NATURE
- B cells and tertiary lymphoid structures promote immunotherapy response
- (2020) Beth A. Helmink et al. NATURE
- ARID1A mutation plus CXCL13 expression act as combinatorial biomarkers to predict responses to immune checkpoint therapy in mUCC
- (2020) Sangeeta Goswami et al. Science Translational Medicine
- The High Level of Tertiary Lymphoid Structure Is Correlated With Superior Survival in Patients With Advanced Gastric Cancer
- (2020) Wenting He et al. Frontiers in Oncology
- The PD-1/PD-L1-Checkpoint Restrains T cell Immunity in Tumor-Draining Lymph Nodes
- (2020) Floris Dammeijer et al. CANCER CELL
- Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial
- (2020) Nick van Dijk et al. NATURE MEDICINE
- Neoadjuvant PD-L1 plus CTLA-4 blockade in patients with cisplatin-ineligible operable high-risk urothelial carcinoma
- (2020) Jianjun Gao et al. NATURE MEDICINE
- A Consensus Molecular Classification of Muscle-invasive Bladder Cancer
- (2019) Aurélie Kamoun et al. EUROPEAN UROLOGY
- Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial
- (2019) Thomas Powles et al. NATURE MEDICINE
- Intra-tumoral tertiary lymphoid structures are associated with a low risk of early recurrence of hepatocellular carcinoma
- (2018) Julien Calderaro et al. JOURNAL OF HEPATOLOGY
- TGFβ attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
- (2018) Sanjeev Mariathasan et al. NATURE
- Impact of Molecular Subtypes in Muscle-invasive Bladder Cancer on Predicting Response and Survival after Neoadjuvant Chemotherapy
- (2017) Roland Seiler et al. EUROPEAN UROLOGY
- Reliability of tumor-infiltrating lymphocyte and tertiary lymphoid structure assessment in human breast cancer
- (2017) Laurence Buisseret et al. MODERN PATHOLOGY
- Tumor-Infiltrating Plasma Cells Are Associated with Tertiary Lymphoid Structures, Cytolytic T-Cell Responses, and Superior Prognosis in Ovarian Cancer
- (2016) D. R. Kroeger et al. CLINICAL CANCER RESEARCH
- Tumor infiltration by Tbet+ effector T cells and CD20+ B cells is associated with survival in gastric cancer patients
- (2015) Audrey Hennequin et al. OncoImmunology
- Dendritic Cells in Tumor-Associated Tertiary Lymphoid Structures Signal a Th1 Cytotoxic Immune Contexture and License the Positive Prognostic Value of Infiltrating CD8+ T Cells
- (2013) J. Goc et al. CANCER RESEARCH
- 12-Chemokine Gene Signature Identifies Lymph Node-like Structures in Melanoma: Potential for Patient Selection for Immunotherapy?
- (2012) Jane L. Messina et al. Scientific Reports
- Unique Ectopic Lymph Node-Like Structures Present in Human Primary Colorectal Carcinoma Are Identified by Immune Gene Array Profiling
- (2011) Domenico Coppola et al. AMERICAN JOURNAL OF PATHOLOGY
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now